Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    SINGLE CELL METHYLATION

    Sol. 75N94025Q00167PresolicitationBETHESDA, MD
    Closed
    STATUS
    Closed
    closed Aug 8, 2025
    POSTED
    Jul 29, 2025
    Publication date
    NAICS CODE
    541715
    Primary industry classification
    PSC CODE
    6640
    Product & service classification

    AI Summary

    The National Institutes of Health intends to award a sole source contract to Scale Biosciences for specialized reagents essential for single-cell methylation sequencing. This acquisition is non-competitive and falls under FAR Part 13 Simplified Acquisition Procedures, with a performance period from August 15, 2025, to August 14, 2026. Interested parties may submit capability statements by August 8, 2025.

    Contract details

    Solicitation No.
    75N94025Q00167
    Notice Type
    Presolicitation
    Posted Date
    July 29, 2025
    Response Deadline
    August 8, 2025
    NAICS Code
    541715AI guide
    PSC / Class Code
    6640
    Primary Contact
    FALZONE, MICHAEL L
    State
    MD
    ZIP Code
    20817
    AI Product/Service
    product

    Description

    INTRODUCTION

    THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

    The National Institutes of Health (NIH), National Institute of Child Health and Human Development (NICHD), Office of Acquisitions (OA) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to:

    Scale Biosciences, Inc.

    5601 Oberlin Dr., Suite 110

    San Diego, CA 92121

    NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE

    The intended procurement is classified under NAICS code 541715 with a Size Standard 1,000.

    REGULATORY AUTHORITY

    The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-99-1, July 16, 2018. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($250,000).

    STATUTORY AUTHORITY

    This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

    GENERAL INFORMATION

    1. Title: Single Cell Methylation

    2. Background Information: These reagents manufactured by Scale Biosciences have become an essential component in modern epigenomic research, enabling the preparation of high-quality samples for single-cell methylation sequencing. This technology is critical for the advanced genomic analysis required by our ongoing research initiatives.

    Scale Biosciences’ reagents are uniquely compatible with the National Institutes of Health (NIH) sequencing core instruments and workflows. After a thorough market review, it has been determined that no other known supplier currently offers reagents that provide equivalent functionality or compatibility for single-cell methylation sequencing at this level of resolution and performance.

    Moreover, Scale Biosciences is the exclusive manufacturer and distributor of these specific methylation reagents and holds the associated patents and/or patent applications protecting the underlying technology. Due to these proprietary rights, no third-party vendors are authorized or capable of supplying equivalent products.

    Given the technological specificity, performance requirements, and intellectual property protections, procurement from Scale Biosciences is the only viable option to meet our scientific and operational needs. This purchase therefore qualifies as a sole source acquisition.

    Period of Performance: August 15, 2025 through August 14, 2026

    CLOSING STATEMENT

    This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

    A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

    All responses must be received by August 8, 2025 at 9:00 AM Eastern time and must reference solicitation number 75N94025Q00167. Responses may be submitted electronically to Mr. Michael Falzone, Contracting Officer at Michael.falzone@nih.gov. Fax responses will not be accepted.

    "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”

    Key dates

    1. July 29, 2025Posted Date
    2. August 8, 2025Proposals / Responses Due

    AI search tags

    Frequently asked questions

    SINGLE CELL METHYLATION is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.